The CD30 lateral flow assay offers a significantly less expensive, quicker, and easier-to-use alternative to both ELISA and traditional immunohistochemistry for the detection of BIA-ALCL. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.